Chalcogen Bonded Directly To The Carbocyclic Ring Of The Bicyclo Ring System (e.g., Tocopherols, Etc.) Patents (Class 549/408)
  • Patent number: 10745371
    Abstract: Provided herein are methods for making an alpha-tocotrienol enriched tocol mixture, such as from a plant or plant-derived material. Also provided herein are simulated moving bed purification methods for tocotrienol compounds such as alpha tocotrienol.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: August 18, 2020
    Assignee: PTC Therapeutics, Inc.
    Inventors: Peter Giannousis, Paul Mollard, Noah M. Benjamin, Jeffrey D. Butler, Olivier Dapremont, James B. Falabella
  • Patent number: 10414744
    Abstract: Provided are a 4-sulfur pentafluoride phenol compound and a preparation method therefor, and a preparation method for a sulfur pentafluoride substituted benzopyran compound. According to the present invention, sulfur pentafluoride salicylaldehyde with multiple substituent groups is synthesized through a plurality of steps by using sulfur pentafluoride phenol as a raw material, and then the sulfur pentafluoride substituted benzopyran compound is synthesized on this basis. The method is simple and convenient, and low in cost; overcomes the defects that, at present, the number of types of sulfur pentafluoride phenols is small, and the synthesis of various sulfur pentafluoride substituted benzopyran compounds cannot be met; and has wide industrial application prospects.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: September 17, 2019
    Assignee: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH CHINESE ACADEMY OF SCIENCES
    Inventors: Yanmei Zhang, John J. Talley, Yican Wang, Chuang He, Jiantong Guan, Yongjie Lin, Micky D. Tortorella
  • Patent number: 9629785
    Abstract: The present invention relates to pharmaceutical compositions comprising mono size droplets of skin whitening agents or salts thereof. In particular, the present invention relates to a stable pharmaceutical composition comprising skin whitening agents or salts thereof along with other pharmaceutically acceptable excipients which possess substantially improved skin whitening effects and also exhibits greater skin permeability. The invention also relates to processes for the preparation of such compositions.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: April 25, 2017
    Assignee: CADILA HEALTHCARE LIMITED
    Inventors: Sunilendu Bhushan Roy, Jay Shantilal Kothari, Shafiq Sheikh, Jitendra Dasharathlal Patel, Jinesh Suresh Pancholi
  • Patent number: 9611200
    Abstract: The present invention relates to a process of manufacturing (6R,10R)-6,10,14-trimethylpentadecan-2-one in a multistep synthesis from a mixture of (5E,9E)-, (5E,9Z)-, (5Z,9E)- and (5Z.9Z)-isomers of 6,10,14-trimethylpentadeca-5,9,13-trien-2-one or 6,10,14-trimethylpentadeca-5,9-dien-2-one. The process is very advantageous in that it forms in an efficient way the desired chiral product from a mixture of stereoisomers of the starting product.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: April 4, 2017
    Assignee: DSM IP ASSETS B.V.
    Inventors: Werner Bonrath, Thomas Netscher, Jonathan Alan Medlock, René Tobias Stemmler, Johannes Tschumi, Gerardus Karel Maria Verzijl, Andreas Hendrikus Maria De Vries
  • Patent number: 9458076
    Abstract: The present invention relates to a process of manufacturing compound having stereogenic centers from a mixture of E/Z isomers of unsaturated compounds having prochiral double bonds. The hydrogenation product has a specific desired configuration at the stereogenic centers. The process involves two asymmetric hydrogenation steps. The process is very advantageous in that it forms the desired chiral product from a mixture of stereoisomers of the starting product in an efficient way.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: October 4, 2016
    Assignee: DSM IP ASSETS B.V.
    Inventors: Werner Bonrath, Thomas Netscher, Jonathan Alan Medlock, René Tobias Stemmler, Gerardus Karel Maria Verzijl, Andreas Hendrikus Maria De Vries
  • Patent number: 9440967
    Abstract: The present disclosure provides biologically active compounds of formula (I): and pharmaceutically acceptable salts thereof, compositions comprising these compounds, and methods of using these compounds in a variety of applications, such as treatment or suppression of diseases associated with decreased mitochondrial function resulting in diminished ATP production and/or oxidative stress and/or lipid peroxidation.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: September 13, 2016
    Assignee: Arizona Board of Regents on Behalf of Arizona State University
    Inventors: Sidney Hecht, Xiaoqing Cai, Omar Khdour, Jose I. Armendariz Guajardo
  • Patent number: 9085547
    Abstract: The present invention relates to a process for isolation of micronutrients from deodorizer distillate comprising free fatty acids, the process comprises the following steps: (i) treating the deodorizer distillate in an esterification step with glycerol, which esterification step is autocatalyzed, producing a feedstock of acyl glycerides, and discharging excess of glycerol and produced water; (ii) transferring the feedstock of acyl glycerides having a water content less than 1500 ppm and a free fatty acid content less than 3 wt % to a transesterification step and treating the feedstock of acyl glycerides with methanol to produce a crude biodiesel product; and (iii) refining the crude biodiesel product in a distillation step, and separating the crude biodiesel product into three fractions 1) fatty acid methyl esters, 2) micronutrient rich product comprising tocopherol, and 3) light hydrocarbons.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: July 21, 2015
    Assignee: ALFA LAVAL CORPORATE AB
    Inventors: Susanne Jonsson, Bent Sarup
  • Publication number: 20150148462
    Abstract: Stabilized composition comprising: -at least one homopolymer or copolymer of ethylene; -at least one tocotrienol or at least a mixture of tocotrienol isomers.
    Type: Application
    Filed: July 24, 2013
    Publication date: May 28, 2015
    Applicant: Versalis S.P.A.
    Inventors: Francesco Masi, Cosimo Carfagna, Pierfrancesco Cerruti, Paola Persico
  • Publication number: 20150111910
    Abstract: Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders.
    Type: Application
    Filed: May 22, 2013
    Publication date: April 23, 2015
    Applicant: AUTIFONY THERAPEUTICS LIMITED
    Inventors: Agostino Marasco, Giuseppe Alvaro, Anne Dècor, Dieter Hamprecht, Paolo Dambruoso, Simona Tommasi
  • Publication number: 20150099894
    Abstract: The present invention relates to an improved process for the production of 4-alkanoyloxy-2-methylbutanoic acid, as well as to the use of such compounds in organic syntheses, especially in processes forming intermediates (building blocks) for the synthesis of organic compounds comprising isoprene (isoterpene) units, such as ?-carotene or other carotenoids (e.g. canthaxanthin, zeaxanthin or astaxanthin) or as vitamin E or vitamin A as well as other structurally similar compounds.
    Type: Application
    Filed: June 5, 2013
    Publication date: April 9, 2015
    Inventors: Werner Bonrath, Jan Schütz, Bettina Wüstenberg, Thomas Netscher
  • Publication number: 20140371232
    Abstract: Provided are cajanine structure analogous compounds, synthesis method and pharmacological effects thereof, the compounds of the present invention having the structure as represented by general formulas I, II, III, IV and V. Also provided are pharmaceutical compositions containing the compounds as active ingredient, and uses thereof; the compounds of the present invention having the pharmacological activities such as anti-virus, anti-virus-infection, nerve protection, anti-metabolic-diseases and the like. Also provided is a chemical total synthesis preparation method of the natural products cajanine, cajanine A and cajanine C. The present invention lays a foundation for the in-depth study and development of the compounds as clinical drugs in the future.
    Type: Application
    Filed: December 18, 2012
    Publication date: December 18, 2014
    Inventors: Zhuorong Li, Xingyue Ji, Situ Xue, Guanghui Zheng, Yuhuan Li, Peizhen Tao, Jiandong Jiang
  • Patent number: 8906960
    Abstract: A transdermal fluid is provided wherein the main ingredient is tocotrienol and curcumin is added to enhance the anti-cancer effects of tocotrienols. The composition is useful for the treatment or prevention of a cancer, a tumor or an inflammatory disorder, particularly breast cancer.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: December 9, 2014
    Assignee: Malaysian Palm Oil Board
    Inventors: Kalanithi Nesaretnam, Kanga Rani Selvaduray
  • Patent number: 8901168
    Abstract: The invention relates to a formulation for supplementation on immune response to a biological substance. More particularly, the formulation consists of one or more forms of Vitamin E which provides a supplementation on immune response to tetanus toxoid. In addition, the present invention also relates on the effect of different types of Vitamin E such as tocotrienol rich fraction, delta tocotrienol and alpha-tocopherol supplementation on immune response to tetanus toxoid vaccination.
    Type: Grant
    Filed: October 1, 2008
    Date of Patent: December 2, 2014
    Inventor: Kalanithi Nesaretnam
  • Publication number: 20140329808
    Abstract: Compositions of matter including (R)-2,5,6,8-tetramethyl-8-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl)-1,2,3,8,9,10-hexahydrochromeno[5,6-e][1,3]oxazine and (R)-2,6,8-trimethyl-8-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl)-1,2,3,8,9,10-hexahydrochromeno[5,6-e][1,3]oxazine are disclosed herein. Further disclosed are methods of preparation of such compounds and the use of such compounds as anticancer agents.
    Type: Application
    Filed: July 21, 2014
    Publication date: November 6, 2014
    Inventors: Khalid A. El Sayed, Paul W. Sylvester, Fathy A. Behery
  • Publication number: 20140301970
    Abstract: Gel-forming block copolymers were prepared comprising i) a central hydrophilic block consisting essentially of a divalent poly(ethylene oxide) chain and ii) two peripheral monocarbonate or polycarbonate hydrophobic blocks. The hydrophobic blocks comprise one or more vitamin-bearing subunits. The vitamin-bearing subunits comprise a carbonate backbone portion and a side chain comprising a covalently bound form of a vitamin. The gel-forming block copolymers can be used to prepare various biodegradable and/or biocompatible hydrogel and organogel drug compositions, in particular antimicrobial and/or anti-tumor drug compositions. The hydrogel compositions can be suitable for depot injections. Synergistic enhancement of toxicity to microbes was observed with compositions comprising an antimicrobial cationic polymer and an antimicrobial compound.
    Type: Application
    Filed: April 9, 2013
    Publication date: October 9, 2014
    Applicants: INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: James L. Hedrick, Ashlynn L. Z. Lee, Victor W. L. Ng, Yi Yan Yang
  • Publication number: 20140296544
    Abstract: The present invention provides a method for converting an aromatic hydrocarbon to a phenol by providing an aromatic hydrocarbon comprising one or more aromatic C—H bonds and one or more activated C—H bonds in a solvent; adding a phthaloyl peroxide to the solvent; converting the phthaloyl peroxide to a di-radical; contacting the di-radical with the one or more aromatic C—H bonds; oxidizing selectively one of the one or more aromatic C—H bonds in preference to the one or more activated C—H bonds; adding a hydroxyl group to the one of the one or more aromatic C—H bonds to form one or more phenols; and purifying the one or more phenols.
    Type: Application
    Filed: August 14, 2013
    Publication date: October 2, 2014
    Inventors: Dionicio Siegel, Andrew M. Camelio, Anders Eliasen, Trevor C. Johnson, Abram Axelrod, Changxia Yuan
  • Publication number: 20140249321
    Abstract: The present invention relates in a first aspect to a process for hydrogenation of ketones having at least a carbon-carbon double bond in the y,8-position to the keto group by hydrogen in the presence of at least one chiral iridium complex of formula (I), where R1 represents a group of formula (II) or (III) or (IV). It has been shown that this process leads to a strong increase in preferential formation of a single isomer. The process is particularly suitable for the hydrogenation of y,8-unsaturated ketones which can be used as flavours and fragrances or for the preparation of vitamin E and its derivatives or of flavours and fragrances.
    Type: Application
    Filed: June 13, 2012
    Publication date: September 4, 2014
    Applicant: DSM IP ASSETS B.V.
    Inventors: Marc-André Mueller, Andreas Pfaltz, Jonathan Medlock
  • Publication number: 20140221351
    Abstract: The present invention relates to novel bis-sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Application
    Filed: April 8, 2014
    Publication date: August 7, 2014
    Applicant: ALLERGAN, INC.
    Inventors: HAIQING YUAN, RICHARD L. BEARD, XIAOXIA LIU, JOHN E. DONELLO, VEENA VISWANATH, MICHAEL E. GARST
  • Publication number: 20140221674
    Abstract: The invention discloses novel processes for production, enrichment and/or isolation of alpha-tocotrienol from source material comprising at least one non-alpha-tocotrienol, such as natural extracts comprising mixed tocotrienols.
    Type: Application
    Filed: September 26, 2013
    Publication date: August 7, 2014
    Applicant: Edison Pharmaceuticals, Inc.
    Inventors: Kieron E. Wesson, Andrew W. Hinman, Orion D. Jankowski
  • Patent number: 8791155
    Abstract: The invention relates to novel chroman derivatives, stereoisomers and pharmaceutically acceptable salts of Formula I wherein the substituents are as defined in the specification. They are useful in the treatment of disorders mediated by lipoxygenase, such as immune diseases, respiratory diseases and cardiovascular diseases, as well as in the treatment of neurodegenerative disorders and/or mitochondria) disorders. They are also useful in the manufacture of pharmaceutical formulations for the treatment of such conditions.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: July 29, 2014
    Assignee: Edison Pharmaceuticals, Inc.
    Inventors: Bing Wang, Gail Walkinshaw, Donald R. James
  • Publication number: 20140205551
    Abstract: The present invention relates to a composition for topical application comprising at least a benzotriazol derivative and vitamin E or a derivative thereof. Furthermore, the invention relates to compositions that prevent staining of clothes and exhibit a reduced sand adherence on skin.
    Type: Application
    Filed: June 6, 2012
    Publication date: July 24, 2014
    Applicant: DSM IP ASSETS B.V.
    Inventor: Christine Mendrok-Edinger
  • Publication number: 20140183409
    Abstract: A liquid crystal composition including an antioxidant, and a liquid crystal display device containing this composition are described. The liquid crystal composition has a nematic phase, has a high solubility in a liquid crystal composition, and includes a specific antioxidant useful for preventing deterioration of the composition. The liquid crystal composition may also include a specific compound having a high maximum temperature or a small viscosity as a first component, a specific compound having a high maximum temperature or a large dielectric anisotropy as a second component, and a specific compound having a large negative dielectric anisotropy as a third component.
    Type: Application
    Filed: December 26, 2013
    Publication date: July 3, 2014
    Applicants: JNC PETROCHEMICAL CORPORATION, JNC CORPORATION
    Inventors: YASUYUKI GOTOH, RYUSHI SHUNDO, NORIKATSU HATTORI
  • Publication number: 20140107139
    Abstract: The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.
    Type: Application
    Filed: June 7, 2012
    Publication date: April 17, 2014
    Applicant: AUTIFONY THERAPEUTICS LIMITED
    Inventors: Giuseppe Alvaro, Anne Decor, Dieter Hamprecht, Agostino Marasco
  • Publication number: 20140097383
    Abstract: A liquid crystal composition and an AM liquid crystal display device are described. The liquid crystal composition contains a specific compound having a small viscosity as a first component, may further contain a specific compound having a large negative dielectric anisotropy as a second component and a specific compound having a small viscosity as a third component, and has a negative dielectric anisotropy and a ratio of rotational viscosity to an elastic constant in the range of 4.2 GPa·s/N or lower. The liquid crystal display device includes the composition.
    Type: Application
    Filed: February 8, 2013
    Publication date: April 10, 2014
    Applicants: JNC PETROCHEMICAL CORPORATION, JNC CORPORATION
    Inventors: Yoshimasa Furusato, Masayuki Saito
  • Publication number: 20140031388
    Abstract: Anticancer compounds according to formula I are described herein. wherein R1, R2, R3 and R4 are selected from H, CH3, OH, SH, OCH3, NHR?, halogen, CF3, N-linked pyrrolidine, and SO2NHR?, or any combination thereof; R5 is an alkyl, alkenyl, or alkaryl group including from 4 to 11 carbons, X is selected from CH2, CHOH, C?O, S?O, O?S?O, and an oxetane ring, Y is selected from CH2, O, and NH, and R? is a H, aryl, or a lower alkyl group, or pharmaceutically acceptable salts thereof. The compounds have been shown to facilitate site-specific dephosphorylation of Akt at Ser-473, thereby inactivating Akt and decreasing dysregulation of Akt signaling that can occur in cancer cells.
    Type: Application
    Filed: July 26, 2013
    Publication date: January 30, 2014
    Inventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp
  • Publication number: 20130317000
    Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: May 21, 2013
    Publication date: November 28, 2013
    Applicants: XENON PHARMACEUTICALS INC., GENENTECH, INC
    Inventors: Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Daniel Ortwine, Brian Safina, Shaoyi Sun, Daniel P. Sutherlin, Alla Yurevna Zenova
  • Publication number: 20130317001
    Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: May 21, 2013
    Publication date: November 28, 2013
    Applicants: XENON PHARMACEUTICALS INC., GENENTECH, INC.
    Inventors: Jean-Christophe Andrez, Sultan Chowdhury, Shannon Marie Decker, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Jun Li, Daniel F. Ortwine, Brian Safina, Tao Sheng, Shaoyi Sun, Daniel P. Sutherlin, Michael Scott Wilson, Alla Yurevna Zenova
  • Publication number: 20130165435
    Abstract: Compositions of matter including (R)-2,5,6,8-tetramethyl-8-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl)-1,2,3,8,9,10-hexahydrochromeno[5,6-e][1,3]oxazine and (R)-2,6,8-trimethyl-8-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl)-1,2,3,8,9,10-hexahydrochromeno[5,6-e][1,3]oxazine are disclosed herein. Further disclosed are methods of preparation of such compounds and the use of such compounds as anticancer agents.
    Type: Application
    Filed: November 30, 2012
    Publication date: June 27, 2013
    Inventors: Khalid A. El Sayed, Paul W. Sylvester, Fathy A. Behery
  • Publication number: 20130158106
    Abstract: Tocol derivative compounds, compositions comprising these tocol derivatives and methods of using the tocol derivatives are provided herein. Specifically the tocol derivatives have a partially unsaturated hydrocarbon tail and are thus distinct from the tocopherols. The hydrocarbon tails do not have a trans carbon-carbon double bond in the second isoprene unit of the hydrocarbon tail and are distinct from the tocotrienols. The compounds are expected to allow improved interaction with the ?-tocopherol transfer protein receptor than the tocotrienols and better bioactivity than the tocopherols.
    Type: Application
    Filed: June 2, 2011
    Publication date: June 20, 2013
    Applicants: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERAN AFFAIRS, THE BOARD OF TRUSTEES FOR THE UNIVERSITY OF ARKANSAS
    Inventors: Philip J. Breen, K. Sree Kumar, Cesar Compadre, Martin Hauer-Jensen, Kottayil Varughese
  • Publication number: 20130096209
    Abstract: The present invention provides edible compositions comprising a compound of the present invention, food products comprising such edible compositions and methods of preparing such food products. The present invention also provides methods of reducing the amount of NaCl in a food product, methods of reducing the sodium intake in a diet, and methods of reducing bitter taste in a food product.
    Type: Application
    Filed: April 15, 2011
    Publication date: April 18, 2013
    Applicants: Kraft Foods Global Brands LLC, Chromocell Corporation
    Inventors: David Hayashi, William P. Jones, Jane V. Leland, Peter H. Brown, Joseph Gunnet, Daniel Lavery, Louise Slade, Kambiz Shekdar, Jessica Langer
  • Patent number: 8414850
    Abstract: A rectification column and system for the working-up of a vitamin E (VE)- and/or vitamin E acetate (VEA)-containing product stream includes purification of a vitamin E-containing product stream, acetylation of at least a part of the purified vitamin E and purification of at least a part of the acetylated vitamin E, the purification of vitamin E and vitamin E acetate preferably being effected by distillation, for example rectification.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: April 9, 2013
    Assignee: DSM IP Assets B.V.
    Inventors: Werner Pietzonka, Peter Ruckstuhl, Angela Wildermann
  • Publication number: 20130052237
    Abstract: A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.
    Type: Application
    Filed: August 29, 2012
    Publication date: February 28, 2013
    Applicant: INTARCIA THERAPEUTICS, INC.
    Inventors: Rom Ezer Eliaz, Yuanpeng Zhang, Catherine Manya Rohloff, Eric William Weeks, Gunjan Junnarkar
  • Patent number: 8378044
    Abstract: Provided is a low-cost, environmentally friendly living radical polymerization catalyst having high activity. The catalyst is used for a living radical polymerization method, and contains a central element consisting of oxygen and at least one halogen atom bound to the central element. Furthermore, an alcohol compound can be used as a catalyst precursor. By polymerizing a monomer in the presence of the catalyst, a polymer having narrow molecular weight distribution can be obtained, and the cost of the living radical polymerization can be remarkably reduced. The present invention is significantly more environmentally friendly and economically excellent than conventional living radical polymerization methods, due to advantages of the catalyst such as low toxicity of the catalyst, low amount of the catalyst necessary, high solubility of the catalyst, mild reaction conditions, and no coloration/no odor (which do not require a post-treatment for a molded article), and the like.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: February 19, 2013
    Assignee: Kyoto University
    Inventors: Atsushi Goto, Takeshi Fukuda, Yoshinobu Tsujii
  • Publication number: 20130041164
    Abstract: ?-tocopherol quinone is chemically reduced by combination with a reducing agent, such as tin (II) ion in the form of stannous chloride (SnCl2-2H20), or by chromium (III) ion, such as chromium (III) in the form of chromium chloride (CrCl3-6H20). Purified ?-tocopherol is obtained from ?-tocopherol formed by reduction of an oxidized ?-tocopherol, such as ?-tocopherol quinone, by tin (II) ion or chromium (III) ion. Purified ?-tocopherol of the invention can be administered to patients in need thereof, ?-tocopherol is preserved by combination with a reducing agent.
    Type: Application
    Filed: April 29, 2011
    Publication date: February 14, 2013
    Inventors: David K. Ryan, Isso Bayala, Eugene Rogers
  • Patent number: 8362071
    Abstract: Vitamin E succinate derivatives according to formula I: are described. These compounds can be included in pharmaceutical compositions, and can be used for the treatment of cancers such as metastatic cancer and as antiadhesive agents.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: January 29, 2013
    Assignee: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp
  • Publication number: 20120277180
    Abstract: Provided herein are methods and systems for identifying one or more cofactors such as vitamins for individuals based on the genetic makeup of the individual by detecting the presence or absence of at least one genetic variant, determining a predisposition to cofactor remediable condition, generating a personalized nutritional advice plan based on the genetic variant. Also provided herein are formulations of cofactors determined by the genetic make-up of the individual and methods of determining and producing these formulations.
    Type: Application
    Filed: September 30, 2010
    Publication date: November 1, 2012
    Applicants: VITAPATH GENETICS, INC, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Nicholas Marini, Jasper Rine, Dennis Austin Gilbert, Bruce Cohen
  • Patent number: 8299277
    Abstract: Administration of either a tocopherol represented by the general formula (1) or a tocotrienol compound ester derivative before or after exposure to radiation is effective in preventing or treating health disorders caused by the radiation exposure.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: October 30, 2012
    Assignees: National Institute of Radiological Sciences, Fukuoka University
    Inventors: Kazunori Anzai, Megumi Ueno, Haruko Yakumaru, Junichi Ueda, Makoto Akashi, Shizuko Kobayashi, Jiro Takata, Nobuo Ikota
  • Publication number: 20120220780
    Abstract: Disclosed are: a ligand for an asymmetric synthesis catalyst; and a process for producing an ?-alkenyl cyclic compound using the ligand. Specifically disclosed are: a ligand for an asymmetric synthesis catalyst, which is represented by any one of formulae (1) to (4) [wherein R1 represents —Cl or —Br; R2 represents —CH3 or —CF3; and R3 represents —CH2—CH?CH2 or —H]; and a process for producing an ?-alkenyl cyclic compound using the ligand.
    Type: Application
    Filed: October 1, 2010
    Publication date: August 30, 2012
    Applicant: National University Corporation Nagoya University
    Inventors: Masato Kitamura, Shinji Tanaka
  • Publication number: 20120157370
    Abstract: The invention relates to the use of radical traps in detergents and cleaners in order to improve cleaning performance, in particular for dirt containing polymerizable dyes.
    Type: Application
    Filed: February 23, 2012
    Publication date: June 21, 2012
    Applicant: Henkel AG & Co. KGaA
    Inventors: Christian Kropf, Andreas Buhl, André Hätzelt
  • Publication number: 20120148498
    Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1?.
    Type: Application
    Filed: February 28, 2012
    Publication date: June 14, 2012
    Applicant: Baylor Research Institute
    Inventors: Jacques Banchereau, Virginia Pascual
  • Publication number: 20120136048
    Abstract: A method for preventing, reducing, ameliorating or treating ophthalmic disorders associated with neurodegenerative diseases or trauma, comprising the topical, periocular, or intraocular application of an ophthalmic formulation comprising a therapeutically effective amount of one or more ophthalmic agents selected from the group consisting of alpha-tocotrienol, beta-tocotrienol, gamma-tocotrienol, delta-tocotrienol, or esters or mixtures thereof is disclosed. Use of tocotrienols for the prevention, reduction, amelioration or treatment of ophthalmic disorders that are, or that are associated with, mitochondrial diseases is also discussed. Topical ophthalmic formulations comprising tocotrienols are also discussed.
    Type: Application
    Filed: April 27, 2010
    Publication date: May 31, 2012
    Inventors: Guy M. Miller, William D. Shrader, Viktoria Kheifets
  • Patent number: 8183396
    Abstract: The invention relates to a process for the working-up of a vitamin E (VE)- and/or vitamin E acetate (VEA)-containing product stream, which is substantially characterized by purification of a vitamin E-containing product stream, acetylation of at least a part of the purified vitamin E and purification of at least a part of the acetylated vitamin E, the purification of vitamin E and vitamin E acetate preferably being effected by distillation, for example rectification.
    Type: Grant
    Filed: August 19, 2005
    Date of Patent: May 22, 2012
    Assignee: DSM IP Assets B.V.
    Inventors: Werner Pietzonka, Peter Ruckstuhl, Angela Wildermann
  • Publication number: 20120122969
    Abstract: Methods of treating or suppressing Pervasive Developmental Disorders (PDDs) including; Autistic Disorder, Asperger's Disorder, Childhood Disintegrative Disorder (CDD), Rett's Disorder, and PDD-Not Otherwise Specified (PDD-NOS) comprising administering to a subject in need thereof a therapeutically effective amount of a tocotrienol, a tocotrienol ester, a tocotrienol ether, a tocotrienol enriched extract or mixtures thereof.
    Type: Application
    Filed: February 25, 2010
    Publication date: May 17, 2012
    Inventor: Guy M. Miller
  • Patent number: 8158329
    Abstract: The present invention provides a compound represented by the formula (I): wherein P1, P2, P3, P4 and P5 each independently represents a hydrogen atom etc., and at least one selected from the group consisting of R1, R2, R3, R4, R5, R6, R7, R8 and R9 is the group represented by the formula (II): wherein X1 and X2 each independently represent a hydrogen atom etc., n represents an integer of 1 to 4, Z1 represents a C1-C6 alkyl group etc., and ring Y represents an alicyclic hydrocarbon group, and the others each independently represent a hydrogen atom, a C1-C6 alkyl group or a hydroxyl group, and a chemically amplified resist composition containing the same.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: April 17, 2012
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: Ichiki Takemoto, Nobuo Ando
  • Patent number: 8148424
    Abstract: The present invention provides an antiproliferative compound having a structural formula where X and Y independently are oxygen, nitrogen or sulfur; R1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxylic acid, carboxylate, carboxamide, ester, thioamide, thiolacid, thiolester, saccharide, alkoxy-linked saccharide, amine, sulfonate, sulfate, phosphate, alcohol, ethers or nitriles; R2 and R3 are hydrogen or R4; R4 is methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide or amine; and R5 is alkenyl; where when Y is nitrogen, said nitrogen is substituted with R6, wherein R6 is hydrogen or methyl. Also provided are methods for treating a cell proliferative disease and for inducing apoptosis in a cell comprising administering this compound is also provided.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: April 3, 2012
    Assignee: Research Development Foundation
    Inventors: Bob G. Sanders, Kimberly Kline, Weiping Yu
  • Publication number: 20120077992
    Abstract: The present invention relates to a device for treatment of material transported through the device comprising at least one porous element consisting of solid, for example metallic, structure which allows cross-flow of the material through the porous element. The invention also relates to various types of uses of the device. A device in accordance with the invention is particularly useful to carry out chemical reactions under homogenous and heterogeneous conditions. Such a device hereinafter also referred as reactor may comprises a tube (1) having a cylindrical wall (2) with one inlet end (3) and one outlet end (4). Arranged in the tube (1) is at least one cylindrical porous element (5) consisting of solid metal structure, wherein said porous element (5) comprises a plurality of hollow spaces that are connected to each other and form an interconnected cavity network and wherein the at least one porous element (5) and the cylindrical wall (2) are made in one piece.
    Type: Application
    Filed: June 14, 2010
    Publication date: March 29, 2012
    Inventors: Cédric Hutter, Francesco Mascarello, Philipp Von Rohr, David Ruppen
  • Patent number: 8080581
    Abstract: The present invention provides a cosmetic having equal to or a higher antioxidant activity and moisture retaining property than the above-described conventional vitamin E derivatives. The cosmetic also has an excellent emulsifying ability and solubilizing ability and remarkably reduces a sticky feeling on the skin (in particular, the sticky feeling during drying after the application on the skin). That is, the cosmetic of the present invention containing a vitamin E derivative represented by the following formula (I) or a salt thereof. [In the formula, R1, R2, and R3 represent a hydrogen atom or a methyl group; R4 represents a C1-6 alkanoyl group, a C1-6 alkyl group, a SO3H group, a P(O)(OH)2 group, a CH2COOH group or a COCH2CH(SO3H)COOH group; EO represents an ethylene oxide group; BO represents a butylene oxide group; k and n independently represent any one of numbers 0 to 30; and m represents any one of numbers 1 to 30.
    Type: Grant
    Filed: December 26, 2007
    Date of Patent: December 20, 2011
    Assignee: Shiseido Company Ltd.
    Inventors: Takayuki Omura, Susumu Yoshida, Yuko Nakanishi, Hiroyuki Kakoki
  • Patent number: 8048913
    Abstract: A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism.
    Type: Grant
    Filed: September 14, 2009
    Date of Patent: November 1, 2011
    Assignees: Australian Health & Nutrition Assoc. Ltd., Children's Hospital Medical Center
    Inventors: Kenneth David Reginald Setchell, Sidney John Cole
  • Patent number: 8044097
    Abstract: The invention relates to novel chroman derivatives, stereoisomers and pharmaceutically acceptable salts of Formula I wherein the substituents are as defined in the specification. They are useful in the treatment of disorders mediated by lipoxygenase, such as immune diseases, respiratory diseases and cardiovascular diseases, as well as in the treatment of neurodegenerative disorders and/or mitochondria) disorders. They are also useful in the manufacture of pharmaceutical formulations for the treatment of such conditions.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: October 25, 2011
    Assignee: Ampere Life Sciences, Inc.
    Inventors: Bing Wang, Jian Chen
  • Publication number: 20110207749
    Abstract: The present disclosure is generally directed to compounds that can inhibit DAGL? and/or ? activity, compositions comprising such compounds, and methods for inhibiting DAGL? and/or ? activity.
    Type: Application
    Filed: February 11, 2011
    Publication date: August 25, 2011
    Inventors: Louis S. Chupak, Xiaofan Zheng, Min Ding, Shuanghua Hu, Yazhong Huang, Robert G. Gentles